We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics


Designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, a... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
29 Aug 2020 - 02 Sep 2020
Virtual Venue

Diagnostic Test Aids Detection of Prosthetic Joint Infections

By HospiMedica International staff writers
Posted on 10 Jun 2019
Print article
Image: The presence of alpha defensin in synovial fluid indicates PJI (Photo courtesy of Zimmer Biomet).
Image: The presence of alpha defensin in synovial fluid indicates PJI (Photo courtesy of Zimmer Biomet).
A new test kit detects periprosthetic joint infection (PJI) in the synovial fluid of patients being evaluated for revision surgery.

The Zimmer Biomet (Warsaw, IN, USA) Synovasure Lateral Flow Test Kit is an in-vitro visual immunochromatographic diagnostic assay designed to detect human alpha defensins 1-3 proteins in the synovial fluid of patients who underwent total joint replacements. The test, which takes approximately 10 minutes to complete, is not intended to identify a specific type of infection, but rather to be used in conjunction with other clinical and diagnostic findings to aid in the diagnosis of PJI. Each kit contains a reagent strip with all of the critical components for the assay.

Synovial fluid is first collected with a disposable tube, and is then diluted by adding it to a premeasured dilution buffer. Three free-falling drops of the diluted sample are added to the test device to begin the testing process. The cellular material is first removed in a filtering pad, and the solution then transfers to a buffering pad, where it mixes with a gold conjugate labeled with the anti-defensin antibody. The test mixture then migrates across test and control lines; a test result line will form if the level of alpha defensin in the sample is greater than the cut-off concentration.

“With this test, health care professionals now have an additional option available to aid their clinical assessment as to whether the patient has an infection and requires revision surgery,” said Tim Stenzel, MD, PhD, of the FDA Center for Devices and Radiological Health (CDRH). “Whereas before surgeons may have opted for surgery when the presence of an infection was unclear, with this test they have more information and could potentially reduce patient risk by avoiding unnecessary revision operations for replacement joints.”

Alpha defensins are antimicrobial proteins released by activated neutrophils in response to microbial products or pro-inflammatory cytokines. The polar topology of alpha defensins, with spatially separated charged and hydrophobic regions, allows them to insert themselves into phospholipid membranes so that their hydrophobic regions are buried within the lipid membrane interior and their charged regions interact with anionic phospholipid head groups and water, resulting in the disruption of membrane integrity and function, ultimately leading to the lysis of microorganisms.

Related Links:
Zimmer Biomet

Print article



view channel

Siemens to Acquire Varian Medical to Create Comprehensive Cancer Portfolio

Siemens Healthineers (Erlangen, Germany) has entered into an agreement to acquire Varian Medical Systems, Inc. (Palo Alto, CA, USA) that will lead to the creation of a global leader in healthcare with... Read more
Copyright © 2000-2020 Globetech Media. All rights reserved.